Anastrozole

Author: Prof. Dr. med. Peter Altmeyer

Our authors

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Astrazole; CAS number: 120511-73-1

Definition
This section has been translated automatically.

Anastrozole is an orally administered active ingredient (mean half-life: approx. 45.0 h) from the group of non-steroidal aromatase inhibitors. By blocking the aromatases, the remaining oestrogen production during and after menopause decreases significantly. A single administration of 1 mg lowers the estrogen level by 70% in 7 days and by up to 80% within 14 days. anastrozole also directly inhibits the aromatase in the tumour cells. And thus limits the growth and spread of the tumor cells.

Anastrozole has no gestagenic, androgenic or estrogenic effect.

Indication
This section has been translated automatically.

Advanced or metastatic breast cancer in postmenopausal patients.

Undesirable effects
This section has been translated automatically.

hot flushes, flush

Tiredness

Headaches

Nausea

Depressions

Insomnia

cholesterol decline

Osteoporosis

Skin changes rarely (see aromatase inhibitors below)

Preparations
This section has been translated automatically.

Arimidex®

Anablock® 1 mg Film coated tablets

AnastroHEXAL® 1 mg Film coated tablets

Note(s)
This section has been translated automatically.

The performance-enhancing effect of anastrozole in female athletes is explained by its estrogen-reducing effect. For example, when the concentration of oestrogen decreases, less water and less fat is stored in the body. This provides female athletes with weight advantages, for example.

Literature
This section has been translated automatically.

  1. Coates AS et al (2014) Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer Robert Koch-Institute Ann Oncol 26: 1533-1546
  2. Cuzick J et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11: 1135-1141
  3. Goss PE (1999) Risks versus benefits in the clinical application of aromatase inhibitors. Endocr Relat Cancer 6: 325-32
  4. Kim YJ et al (2020) Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events. Dermatol Ther (Heidelberg) 10:221-229.

Authors

Last updated on: 29.10.2020